SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: Because frequent mutations affecting JAK/STAT downstream signaling were observed in samples from patients with CTCL, targeted inhibition of this pathway demonstrated that aberrant CTCL growth was controlled by this signaling.